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The Gn subcomponent of the Gn-Gc assembly that
envelopes the human and animal pathogen, Rift Val-
ley fever virus (RVFV), is a primary target of the
neutralizing antibody response. Tobetter understand
the molecular basis for immune recognition, we
raised a class of neutralizing monoclonal antibodies
(nAbs) against RVFV Gn, which exhibited protective
efficacy in a mouse infection model. Structural char-
acterization revealed that these nAbs were directed
to themembrane-distal domain of RVFVGn and likely
preventedvirus entry into ahost cell byblocking fuso-
genic rearrangements of the Gn-Gc lattice. Genome
sequence analysis confirmed that this region of the
RVFV Gn-Gc assembly was under selective pressure
andconstitutedasiteof vulnerability on the virion sur-
face. These data provide a blueprint for the rational
design of immunotherapeutics and vaccines capable
of preventing RVFV infection and a model for under-
standing Ab-mediated neutralization of bunyaviruses
more generally.
INTRODUCTION
First reported in 1931 (Daubney et al., 1931), Rift Valley fever
virus (RVFV) is an arbovirus endemic to Africa and the Arabian3750 Cell Reports 25, 3750–3758, December 26, 2018 ª 2018 The A
This is an open access article under the CC BY license (http://creativepeninsula that causes recurrent epidemics and epizootics.
RVFV is of both agricultural and biomedical importance, as infec-
tion of livestock results in high incidences of neonatal mortality
and zoonosis; human disease ranges from mild self-limiting
febrile illness to severe disease characterized by hemorrhagic di-
atheses, encephalitis, and ocular pathologies (Al-Hazmi et al.,
2003; Mohamed et al., 2010; Sow et al., 2014). Human popula-
tions throughout East Africa are at high risk for RVFV infection,
with seroprevalence reported to exceed 8% in communities
located near water reservoirs that support mosquito populations
(Pourrut et al., 2010). No licensed antivirals or vaccines for RVFV
are currently available, although a number of vaccine candidates
are in development (Dungu et al., 2018; Faburay et al., 2017).
The genetically diverse group of viruses within the genus Phle-
bovirus, family Phenuiviridae, currently contains ten species
(Adams et al., 2017). Like all known phleboviruses, RVFV is
enveloped and contains a single-stranded, negative- or ambi-
sense RNA genome that is divided into three segments: S, M,
and L. The M segment encodes the glycoprotein precursor,
which is processed into twomembrane-anchored glycoproteins,
Gn and Gc (Gerrard and Nichol, 2007). While the phleboviral Gc
forms a class II fusion architecture observed in a number of viral
families (Dessau and Modis, 2013; Guardado-Calvo et al., 2017;
Halldorsson et al., 2016; Vaney and Rey, 2011; Zhu et al., 2017),
the multi-domain phleboviral Gn is structurally distinct and ex-
hibits partial secondary structure similarity with the Gn of hanta-
viruses and the E1 of alphaviruses (Guardado-Calvo and Rey,
2017; Halldorsson et al., 2018; Li et al., 2016; Rissanen et al.,
2017; Voss et al., 2010; Wu et al., 2017). In contrast to theuthor(s).
commons.org/licenses/by/4.0/).
Figure 1. Immunization with Recombinant RVFV Gn Elicits a Robust
IgG Response
(A) Domain organization of the RVFVM segment. The full-length ectodomain of
RVFV Gn was used for immunization. The RVFV Gn construct used for crys-
tallization is colored according to structural identified domains: domain A
(cyan), b-ribbon domain (b, magenta), and domain A (green). The signal pep-
tide (SP), NSm protein, transmembrane region (TM), and Gc glycoprotein are
annotated.
(B) Timeline of rabbit immunization experiments. Rabbits were immunized with
recombinant RVFV Gn and boosted at 4 week intervals. Seven days following
the second boost, RVFV Gn binding and neutralization titers weremeasured. A
splenectomy was performed 7 days following the third boost. mAbs were
derived by hybridoma fusion from splenocytes and antigen-specific single B
cell sorting of PBMCs.
(C) ELISA measuring the titers of IgG specific to RVFV Gn for each rabbit
(rabbits 8312–8315) following the third boost. Sample 8315-0 is a pre-immu-
nization sera control derived from rabbit 8315.
See also Figure S1. Error bars represent the range of the value for experiments
performed in duplicate (not shown when smaller than symbol size).phleboviral Gc, which is structurally well conserved, studies of
RVFV Gn and SFTSV Gn have revealed that the phleboviral Gn
maintains a low level of structural conservation across the family
(approximately 3 A˚ root-mean-square deviation [RMSD]) (Wu
et al., 2017).
Heterodimers of RVFV Gn and Gc form pentameric and hex-
americ assemblies on the virion surface in an icosahedral
T = 12 organization (Freiberg et al., 2008; Halldorsson et al.,
2018; Sherman et al., 2009). Structural studies localize the N-ter-
minal domains of RVFV Gn to the membrane-distal region and
have proposed that it functions as a molecular shield that
protects against premature fusogenic rearrangements of the
cognate Gc (Halldorsson et al., 2018). Host-cell entry of RVFV
is instigated by attachment of Gn-Gc-associated oligoman-
nose-type glycans to the C-type lectin DC-SIGN (Crispin et al.,
2014; Lozach et al., 2011; Phoenix et al., 2016). Following caveo-lae-mediated endocytic uptake, displacement of the Gn is ex-
pected to expose the Gc and allow fusion of the virion and
cellular membranes in a histidine-triggered pH-dependent pro-
cess (de Boer et al., 2012; Halldorsson et al., 2016; Harmon
et al., 2012; Lozach et al., 2010).
Recovery from RVFV infection is associated with the develop-
ment of high titers of neutralizing antibodies, which convey long-
lasting protection against further infection (Bird and Nichol,
2012; Madani et al., 2003; Sabin and Blumberg, 1947). Although
antibodies are elicited against structural and non-structural pro-
tein components of the phlebovirus during infection (Boshra
et al., 2011; Brown et al., 1957; Fernandez et al., 2012; Zaki
et al., 2006), neutralizing monoclonal antibodies (nAbs) are
predominantly raised against the Gn and Gc glycoproteins,
revealing them to be important targets for vaccine and antiviral
design (Faburay et al., 2017).
We sought to investigate the molecular basis of RVFV neutral-
ization by the humoral immune response. Using recombinant
RVFV Gn as an immunogen, we isolated a class of Gn-specific
rabbit monoclonal nAbs, which protect against RVFV challenge
in a murine infection model. X-ray crystallographic analysis re-
veals that these nAbs target the membrane-distal head region
of RVFV Gn. These data provide a molecular rationale for under-
standing Ab-mediated targeting of RVFV and establish a domain
on RVFV Gn as a region of immune vulnerability on the phlebovi-
ral surface.
RESULTS
RVFV Gn Glycoprotein Elicits a Protective Neutralizing
Ab Response
As neutralizing Abs raised during infection and immunization
have been shown to target the phleboviral Gn (Faburay et al.,
2017), we hypothesized that recombinantly expressed RVFV
Gn would constitute an effective immunogen and could be
used to elicit nAbs. We immunized four New Zealand white rab-
bits with RVFV Gn and, following the second boost, observed a
potent neutralizing IgG response against the glycoprotein (Fig-
ures 1A–1C; Table S1).
We sought to understand the molecular mechanism underly-
ing the response generated by immunization. We isolated
approximately 100 hybridomas and screened their supernatants
for RVFV neutralization potency. This analysis revealed that
approximately one-third of the hybridomas were able to
neutralize RVFV in vitro, demonstrating that our RVFV Gn
construct is an effective immunogen. From the isolated hybrid-
omas, we recovered sequences for the heavy- and light-chain
pairings for two strongly binding monoclonal antibodies
(mAbs), termed RV-Gn1 and RV-Gn2. We further isolated an
additional strongly binding mAb, termed RV-Gn3, by antigen-
specific single B cell sorting of peripheral blood mononuclear
cells (PBMCs) (Figures 2A, S1, and S2). A plaque reduction
neutralization test (PRNT) demonstrated that each of the three
mAbs neutralized RVFV with half-maximal inhibitory concentra-
tion (IC50) values ranging from 2.1 to 3.0 mg/mL (Figure 2B).
RV-Gn1, RV-Gn2, and RV-Gn3 exhibit high levels of sequence
conservation in the complementarity-determining regions
(CDRs) of each respective fragment antigen binding (Fab) regionCell Reports 25, 3750–3758, December 26, 2018 3751
Figure 2. High-Affinity mAbs RV-Gn1–3 Are Neutralizing, Target-Overlapping Epitopes on RVFV Gn and Protect against RVFV Infection in a
Mouse Model
(A) ELISA analysis of mAbs RV-Gn1, RV-Gn2, and RV-Gn3 titrated with RVFV Gn. Experiments were performed in duplicate and repeated three times. A
representative dataset is shown.
(B) RVFV-Gn1, RVFV-Gn2, and RVFV-Gn3 neutralize RVFV in a plaque reduction neutralization test. Data are shown as percentage reduction in plaques
compared with the mAb control, and a non-linear regression model is fitted using GraphPad Prism. Experiments were performed in duplicate.
(C) Competition ELISA analysis: overlap of RV-Gn1–3 epitopes were determined by binding of full-length IgG to RVFV Gn in the presence of RV-Gn1 Fab. Ex-
periments were performed in duplicate and repeated three times. A representative dataset is shown. Error bars in (A)–(C) represent the range of the value for
experiments performed (not shown when smaller than symbol size).
(D) Timeline of mouse protection experiments. Mice (n = 6) were given RV-Gn1 or control antibody 8 hr prior to infection with RVFV. Clinical signs of infection and
survival were recorded over 14 days.
(E) Weight loss was recorded over the time course of the experiment. Error bars represent the SEM (not shown when smaller than symbol size).
(F) Efficacy of antibody protection was assessed by a survival analysis. A Kaplan-Meier log rank test was performed; p = 0.03 between RV-Gn1-treated and mAb
control, p = 0.008 between RV-Gn1-treated and no-treatment control, p = 0.08 between mAb control and no-treatment control.
See also Figure S2 and Tables S1 and S2.(Figure S2). Furthermore, analysis of germline V, J, and D seg-
ments suggests that these mAbs are likely clonally related,
with 8%–12% mutation from germline (combined V and J) for
both the heavy and light chains (Table S2; Lefranc et al., 1999).
An ELISA-based competition assay indicates that these closely
related mAbs target a common epitope (Figure 2C). The com-
monalities in sequence, binding affinity, and epitope suggest
that RV-Gn1, RV-Gn2, and RV-Gn3 can be categorized as a sin-
gle class of nAb.
To determine whether this class of anti-RVFVGn nAb also pro-
tects against disease, female BALB/c mice were intravenously
administered with 10 or 200 mg of RV-Gn1 8 hr prior to challenge
with 20 plaque-forming units of RVFV (strain ZH501). Mice were
monitored for disease 14 days post-infection. While none of the
untreated mice survived RVFV challenge, a 40% survival rate3752 Cell Reports 25, 3750–3758, December 26, 2018was observed for the IgG isotype control group, and 100%
survival rate was observed for the RV-Gn1-treated mice, irre-
spective of the RV-Gn1 dose used (Figures 2D–2F). A significant
difference was observed between the RV-Gn1-treated mice and
the isotype controls (p = 0.03, Kaplan Meier with log rank).
Although we observed increased survival in the isotype control
group compared with the no-treatment control group, this was
not significant (p = 0.08). We suggest that the increased survival
rate in the IgG control group may either reflect a feature of the
animal system used, as has been observed in other protection
studies against emerging viruses (Zhao et al., 2017), or be a
non-specific effect of treatment with IgG. Nevertheless, the
100%survival of mice following treatment with RV-Gn1 indicates
the therapeutic potential of anti-RVFV mAbs, which target the
virus surface.
Figure 3. Structural Basis for RV-Gn1-Mediated Neutralization of RVFV
(A) Crystal structure of recombinantly expressed monomeric RVFV Gn in complex with the Fab fragment of RV-Gn1. Domain B of RVFV Gn is shown as a blue
cartoon. The b-ribbon domain and domain A (light blue cartoon) were cleaved during crystallogenesis and are modeled by superposition with the previously
reported crystal structure of unliganded RVFV Gn (PDB: 6F8P) (Halldorsson et al., 2018). VH, VL, CH1, and CL denote the antibody variable heavy, variable light,
constant heavy 1, and constant light chain domains, respectively. Complementarity-determining regions (CDRs) are colored shades of pink (heavy chain) and
green (light chain).
(B) Crystal structure of SFTSV Gn in complex with Fab 4-5 (PDB: 5Y11) (Wu et al., 2017), as presented in (A).
(C) Sequence alignment of SFTSV Gn (residues 251–310) and RVFV Gn (residues 370–439) (calculated by Clustal Omega [Sievers et al., 2011] and plotted with
ESPript [Robert and Gouet, 2014]). Black squares around residues indicate identity. Colored squares below the sequence mark residues forming contacts with
either RV-Gn1 (upper) or SFTSV Gn 4-5 (lower). Residues contacted by the heavy (VH) chain and light chain (VL) are shown in pink and green, respectively.
Residues contacted by both chains are shown in gray.
(D) Footprints of RV-Gn1 and Fab 4-5 plotted onto RVFV Gn domain B and SFTSV domain B, respectively, reveals contrasting modes of antigen recognition.
Upper: antibody footprints mapped onto domain B of RVFV Gn (RV-Gn1, left) and SFTSV Gn (4-5, right). Structures are shown in surface representation with
residues colored as annotated in (C) Lower left: structure overlay of domain B from RVFV Gn (blue) and SFTSV Gn (white) revealed a 1.8 A˚ root-mean-square-
deviation (RMSD). Lower right: structure-based mapping of sequence conservation between RVFV Gn and SFTSV Gn. RVFV Gn is shown in surface repre-
sentation with identical residues colored red and non-conserved residues colored white.
(E) ELISA analysis reveals that RV-Gn1 does not bind SFTSVGn.Wells were coated with SFTSVGn or RVFV Gn and titrated with RV-Gn1 (performed in triplicate).
The dotted line indicates background binding observed in the negative control. Error bars represent the SEM (not shown when smaller than symbol size).
See also Figure S3 and Table S3.RV-Gn nAbs Target Domain B of RVFV Gn
Previous structural analysesofRVFVGnhave revealeda triangular
organization composed of three domains: domain A (residues
154–300), domain B (residues 366–439), and a b-ribbon domain
(residues 301–365 and 440–469) (Halldorsson et al., 2018; Wu
et al., 2017). We sought to ascertain the epitopes targeted on
RVFV Gn by our class of protective nAbs (RV-Gn1–3) and the
molecular basis for mAb-mediated neutralization. Following
complexation of recombinantly derived RVFV Gn monomer with
the Fab region of RV-Gn1, which suggested a 1:1 RVFV Gn-Fab
stoichiometry (Figure S3), we crystallized and determined the
structure of the complex to 1.98 A˚ resolution (Figure 3A; Table S3).
The two complexes of RVFV Gn-Fab RV-Gn1 in the asym-
metric unit exhibit near-identical RVFV Gn binding modes, with
both binding to the apex of domain B in the Gn (0.5 A˚ RMSD).
Interestingly, only residues constituting domain B were resolvedin our crystallographic dataset (residue numbers 370–379 and
397–437). Electron density corresponding to both domain A
and the b-ribbon domain of RVFV Gn was not visible and could
not be sterically accommodated in the RVFV Gn-Fab RV-Gn1
crystal, indicating that these regions were likely cleaved during
crystallogenesis.
Although CDR loops from both the heavy and light chains of
RV-Gn1 contribute to the approximately 800 A˚2 interface, the
heavy chain dominates and forms 12 of 15 hydrogen bonds in
the protein-protein interaction. Loops 405–431 and 423–431 of
domain B in RVFV Gn play a central role in the interaction and
maintain a conformation observed in unliganded structures of
RVFVGn, consistent with the high level of structural similarity be-
tween nAb-bound and nAb-free RVFV Gn structures (1.1 A˚
RMSD). Furthermore, we note that RV-Gn1 residues that form
the paratope are highly conserved with RV-Gn2 and RV-Gn3Cell Reports 25, 3750–3758, December 26, 2018 3753
Figure 4. RVFV-Gn1 Recognizes the Membrane-Distal Surface of the RVFV Gn-Gc Assembly
(A) Modeling of RV-Gn1 Fab onto RVFV Gn-Gc heterodimers (PDB: 6F9F) reveals an epitope proximal to Gc-resident hydrophobic fusion loops. RVFV Gc is
colored according to domain, with domain I in red, domain II in yellow, and domain III in blue. Right: modeling of RV-Gn1 onto the pentameric assembly of RVFV
Gn-Gc heterodimers (PDB: 6F9F). Density corresponding to the cryoelectron microscopy-derived reconstruction of the RVFV virion (EMD: 4201) is shown as a
transparent surface, with transmembrane regions and leaflets of the virion lipid-bilayer membrane annotated.
(B) The RV-Gn1 epitope is sterically accessible to full occupancy across the RVFV virion. RV-Gn1 is shown in green, and the Gn-Gc complex assembly of RVFV
(EMD: 4197) is shown in gray.(Figure S2), suggesting that all of our identified Abs use a highly
similar mode of antigen recognition.
We note that a neutralizing Ab (MAb 4-5) has also been struc-
turally characterized in complex with the Gn of SFTSV (Wu et al.,
2017), a genetically, antigenically, and structurally distal relative
of RVFV that shares only 24% sequence identity in Gn (Figures
3B–3D; Cui et al., 2015; Yu et al., 2011). Interestingly, although
RV-Gn1 and MAb 4-5 use distinct modes of binding with dissim-
ilar CDR loop usage, contact antigenically distinctive surfaces,
and do not cross-react with Gns by ELISA (Figure 3E), their epi-
topes localize to domain B of their respective phleboviral Gn (Fig-
ure 3), suggesting that the Ab-mediated targeting of this portion
of the molecule may be a universal feature of immune responses
to phleboviruses and therefore a common domain for immu-
nogen design strategies.
To map the location of the RV-Gn1 epitope in the context of
the mature RVFV virion, we superimposed the Gn component
of our crystallized Fab-Gn complex onto a reported model of
assembled RVFV Gn-Gc (Figures 4A and 4B; Halldorsson
et al., 2018). This model of the entire RVFV virion reveals that
Fab RV-Gn1 targets the membrane-distal region of the glyco-
protein assembly in a binding mode that extends the Fab
perpendicularly from the virion surface (Figure 4A). Although a
1:1 Fab-to-RVFV Gn stoichiometry could be achieved across
the entire virion (Figure 4B), given the size of the corresponding
Fc region, it is unlikely that this level of occupancy is required
to sterically preclude virus-host interactions.
Immune-Accessible Domain B of RVFV Gn Is under
Selective Pressure
Our structural analysis provides amolecular rationale for the way
in which RV-Gn1–3 targets and neutralizes RVFV (Figures 3A
and 4). We sought to investigate the evolutionary selective pres-
sures acting on RVFV Gn and to assess whether the identified
RV-Gn1 epitope may be targeted by Abs developed during nat-
ural infection. Using 98 publicly available gene sequences of
RVFV Gn-Gc sampled between 1951 and 2010, we performed3754 Cell Reports 25, 3750–3758, December 26, 2018a comparative analysis of non-synonymous to synonymous
nucleotide substitution ratios (dN/dS) in order to identify regions
of the Gn-Gc complex assembly that exhibit greater positive se-
lection for amino acid change (i.e., higher dN/dS ratios).
In this analysis, we observe that the absolute rate of nucleotide
substitution for RVFV Gn-Gc (33 104 substitutions/site/year)
is an order of magnitude lower than that of the envelope glyco-
proteins from fast-evolving viruses such as HIV-1 (Env; 2–5 3
103 substitutions/site/year) (Patin˜o-Galindo and Gonza´lez-
Candelas, 2017), HCV (E1/E2; 1–3 3 103 substitutions/site/
year) (Gray et al., 2011), and seasonal influenza (HA; 5.7 3
103 substitutions/site/year) (Rambaut et al., 2008). Interest-
ingly, division of the RVFV M segment into Gn and Gc glycopro-
tein components reveals that the Gn (dN/dS = 0.075) exhibits a
marginally higher mean dN/dS than the cognate Gc (dN/dS =
0.054) (Figure 5A). Although this observation is consistent with
a higher selective pressure on Gn, it provides limited insight,
because the difference in dN/dS ratios is small and because sub-
stitution rates are averaged across all codons within the protein.
Because most residues are under strong negative selection,
such averaging can mask strong heterogeneity in positive selec-
tion pressure among subgenic regions.
We therefore subdivided RVFV Gn into its structurally
observed A, B, and b-ribbon domains and calculated dN/dS
separately for each domain. This additional analysis indicates a
significantly higher dN/dS ratio (0.135) for domain B (Figure 5B).
This result supports the hypothesis that Gn domain B of the
RVFV Gn-Gc complex is subject to the greatest level of im-
mune-mediated selective pressure. Furthermore, the previous
observation that this region of SFTSV Gn is also targeted by
nAbs (Figures 3B and 3D; Wu et al., 2017) suggests that domain
B of the Gn may be an immunodominant region among phlebo-
virusesmore generally.We note that amino acid diversification of
this region, although slow, may also be facilitated by a greater
level of structural plasticity in RVFV Gn domain B compared
with other domains, as has been previously inferred in structural
studies of the entire RVFV virion (Halldorsson et al., 2018).
Figure 5. Sequence Diversification across RVFV Gn and Gc Glyco-
proteins
Site-wise dN/dS analysis of the RVFVGn andGc. Comparison of dN/dS values
between (A) Gn and Gc and (B) structural domains of RVFV Gn, as defined in
Figure 1A. Error bars show the 95% highest posterior density intervals, and
circles indicate mean values.DISCUSSION
The assembly of Gn and Gc glycoproteins that encapsulate the
surface of RVFV constitutes a primary target of the nAb response
generated during both natural infection and immunization (Fab-
uray et al., 2017). Immunization of rabbits with the monomeric
N-terminal ectodomain of RVFV Gn was sufficient to elicit a
highly neutralizing Ab response in rabbits (Figure 1; Table S1).
These data confirm the Gn glycoprotein as a desirable compo-
nent of any humoral-based vaccine against RVFV and provide
a rational platform for guiding immunogen design efforts for at
risk human and animal populations.
We further derived RVFV Gn-specific Abs (RV-Gn1–3) using
two complementary techniques: hybridoma fusion from spleen
and antigen-specific single B cell sorting of PBMCs. Interest-
ingly, these mAbs (RV-Gn1–3) appear to constitute a single
class of nAb, as they recognize an overlapping RVFV Gn
epitope and likely originate from a single germline (Figure S2).Structural elucidation of RV-Gn1 in complex with RVFV Gn
reveals an 800 A˚ epitope on domain B of RVFV Gn and pro-
vides a molecular basis for immune-mediated neutralization
(Figure 3A). Interestingly, this region of the Gn has been shown
to shield the Gc against premature fusogenic rearrangements
and shifts position upon exposure of RVFV to acidic pH (Hall-
dorsson et al., 2018). Given the close proximity of the RV-
Gn1 epitope to the Gn-Gc interface, it is likely that it func-
tions to sterically impede rearrangements to the glycoprotein
surface of RVFV, preventing exposure of the RVFV Gc-resident
hydrophobic fusion loops in the endosomal membranes
following virion uptake into the host cell (Figure 6). However,
we cannot preclude the possibility that RV-Gn1 may also
disrupt attachment of DC-SIGN to some of the heterogene-
ously distributed oligomannose-type glycans presented on
RVFV Gn and Gc (Lozach et al., 2011; Phoenix et al., 2016).
It will be of interest to assess if this immunogen-elicited
mode of neutralization is reciprocated during natural human
and animal infection.
Despite the genetic, antigenic, and structural differences be-
tween the Gn of RVFV and SFTSV (Figures 3C and 3D), the isola-
tion of a nAb from a humanSFTSV survivor that targets a similarly
localized neutralizing epitope on domain B of SFTSV Gn (Fig-
ure 3B) supports a common mechanism of neutralization and
is suggestive that this domain of the Gn may constitute a site
of vulnerability for phleboviruses more broadly. This hypothesis
is supported by our evolutionary analysis of RVFV Gn-Gc, which
reveals that amino acid diversification of domain B is greater
than that of the rest of the Gn-Gc assembly and is likely sub-
jected to a greater level of immune-mediated selective pressure
compared with other regions (Figure 5). Interestingly, however,
the overall rate of diversification of evolution in domain B (and
Gn-Gc) is still limited compared with other well-characterized
viruses, including HIV-1 (Patin˜o-Galindo and Gonza´lez-Can-
delas, 2017), influenza virus (Rambaut et al., 2008), and HCV
(Gray et al., 2011), suggesting that a multivalent vaccine, such
as that being developed against influenza virus, may protect
against immune escape in this region (Thompson et al., 2018).
Given the analogous putative role of the Gn glycoprotein in pro-
tecting the Gc-resident fusion loops in hantaviruses (Li et al.,
2016), it will be of interest to determine whether this mechanismFigure 6. A Schematic Model of RV-Gn1-
Mediated Neutralization
Domain B-targeting nAbs sterically impede the
exposure of Gc-resident hydrophobic fusion
loops. In the absence of RV-Gn1, fusion loops
encoded in the Gc glycoprotein are able to extend
and insert into endosomal membranes of the host
cell, facilitating fusion.
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of neutralization will also be observed among other families
within the Bunyavirales.
The existence of an immunodominant region on the surface of
phleboviruses has important implications for the development of
glycoprotein therapeutics. For example, a reverse vaccinology
approach (Burton, 2017) that focuses on domain B of the Gn
may benefit immunogen design efforts for pathogenic phlebovi-
ruses for which there are no established vaccines, such as
SFTSV or Toscana virus. Indeed, the development of such a pro-
tein subunit vaccine may also provide an attractive alternative to
live-attenuated or inactivated RVFV vaccines, such as MP-12
and TSI-GSD-200, respectively (Dungu et al., 2018), by immuno-
focusing the Ab response to a vulnerable region of the virion.
Thedevelopment of antiviral biologics hasproved tobeahighly
effective strategy toprotect against emerging viral pathogens (Jin
et al., 2017). Our study provides an initial benchmark for the deri-
vation of highly potent therapeutic Abs from immunization or
convalescent sera that can be used for the treatment or preven-
tion of RVFV infection. Demonstration of the in vivo protective ef-
ficacy of ourmAb,RV-Gn1, in animals highlights thepotential util-
ity of RVFV-specific nAbs as prophylactics. By analogy withmAb
cocktails developed against EBOVGP (Qiu et al., 2012), we antic-
ipate that the identification of nAbs specific to other spatially
distinct epitopes on the surface of the RVFV Gn-Gc complex as-
sembly will be an important consideration for the development of
synergetic, non-competing combinations of anti-RVFV mAbs.STAR+METHODS
Detailed methods are provided in the online version of this paper
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Rabbits
The rabbit immunization study was approved and carried out in accordance with protocols provided to the Institutional Animal Care
and Use Committee (IACUC) at The Scripps Research Institute (TSRI; La Jolla, CA) under approval number #07-0021. The rabbits
were kept, immunized, and bled at TSRI in compliance with the AnimalWelfare Act and other federal statutes and regulations relating
to animals, and in adherence to the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011). Four male
8–10 week old New Zealand White rabbits were used in immunization studies.
Mice
All murine procedures with animals were undertaken according to the United Kingdom Animals (Scientific Procedures) Act 1986.
These studies were approved by the ethical review process of Public Health England, Porton Down, UK, and by the Home Office,
UK via Establishment License 70/1707 and project license P82D9CB4B. A set of humane end points based on clinical manifestation
of disease were defined in the protocol of the project license. Female BALB/c 6-8 week old mice were used in these experiments.
Cell lines
HEK293F female embryonic kidney cells were cultured in Freestyle 293F expression media (GIBCO, Thermofisher). HEK293T female
human embryonic kidney cells were cultured in DMEM supplemented with 10% FCS, non-essential amino acids and L-glutamine.
(GIBCO, Thermofisher). Female vero cells were cultured in DMEMwith 10% FCS. Hybridoma cell lines were generated commercially
by Epitomics. Hybridoma cell cultures were grown in hybridoma SFmedia (Life Technologies). Cell lines were maintained in a humid-
ified incubator at 37C, supplied with 5%–8% CO2. HEK293F cells were agitated at 135 rpm. Cell lines were not authenticated
following purchase.
METHOD DETAILS
Immunization of rabbits with recombinant RVFV Gn
Four male 8–10 week old New ZealandWhite rabbits were primed (intramuscularly) with the full-length RVFV Gn ectodomain (120 mg)
adjuvanted with AdjuplexTM (Sigma Aldrich) (Wegmann et al., 2015) at a ratio of 1:5 adjuvant to immunogen in sterile PBS (1 mL total
volume). Following immunization, a further two boosts were conducted at four week intervals. The final boost for rabbit 8315 was at
week 16 and was performed intravenously seven days before Ab isolation. Sera were prepared from blood collected prior to immu-
nization and seven days following each immunization/boost.
Murine RVFV infection model
Female BALB/c 6-8 week old mice were housed in groups of three. Groups of six mice (randomly assigned, two boxes per group)
were treated intravenously with RV-Gn1 (200 mg or 10 mg) or received no treatment. An additional control group of five mice was
treated with 200 mg of a non-RVFV rabbit mAb control. Four to six hours post-treatment, mice were challenged subcutaneously
with 20 pfu of RVFV, strain ZH501. Mice were monitored six times daily for symptoms of infection and were culled when the deter-
mined humane endpoint was reached. Mouse survival was analyzed using a Kaplan-Meier test with log-rank using GraphPad Prism.
mAb isolation by hybridoma fusion
Seven days following the final boost for rabbit 8315, a spleenectomy was performed and hybridoma cell lines were generated and
then selected by screening the cell supernatant for RVFV neutralization potency (Epitomics). Hybridoma cell cultures were grown for
7–10 days. mAbs were purified from cell supernatant using a Protein G column and buffer exchanged to 10 mM Tris pH 8.0 150 mM
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Phleboviral Gn expression
The cDNA of the RVFV Gn glycoprotein (UniProt accession number P21401) was synthetized by GeneArt (Life Technologies). Two
RVFV Gn constructs were cloned into the pHLSec mammalian expression vector (Aricescu et al., 2006): the ectodomain construct
for immunization (residues 192–560) and a short crystallization construct representing the residues observed in our previously re-
ported structure of RVFV Gn (residues 168–483) (Halldorsson et al., 2018). The SFTSV Gn glycoprotein (UniProt accession number
R4V2Q5) residues 20–341 was synthetized and subcloned as described above. Proteins were expressed in transiently transfected
(HEK) 293T cells (ATCC CRL-1573). Cell supernatants were harvested four days following transfection, and purified by immobilized
nickel-affinity chromatography (5 mL HisTrap FF crude column and A¨KTA FPLC system, GE Healthcare) followed by size exclusion
chromatography (SEC).
Antigen-specific B cell sorting
PBMCs were purified from rabbit 8315 seven days after the third boost using a Lymphoprep (STEMCELL Technology) density
gradient. PBMCs were cryopreserved in FBS plus 10% DMSO. Fluorescence-activated cell sorting of cryopreserved PBMCs was
performed. PBMCs were stained with anti-CD3-FITC (Santa Cruz Biotechnology), anti-IgM-PE (Southern Biotech), anti-IgG-
PerCP-Cy5.5 (Santa Cruz Biotechnology) and hexahistidine-tagged RVFV-Gn. Cells were washed and anti-HIS-APC (Abcam) was
added. CD3-IgM-IgG+RVFV Gn+ cells were sorted into individual wells containing RNase OUT (Invitrogen), First Strand SuperScript
III buffer, DTT and H2O (Invitrogen) and RNA was converted into cDNA (SuperScript III Reverse Transcriptase, Invitrogen) using
random hexamers following the manufacturer’s protocol.
Full-length Ab cloning and expression
The rabbit Ab variable regions of heavy and kappa chains were PCR amplified using previously described primers and PCR condi-
tions (Table S4) (McCoy et al., 2016). PCR products were purified and cloned into an expression plasmid adapted from the pFUSE-
rIgG-Fc and pFUSE2-CLIg-rK1 vectors (InvivoGen) using the Gibson Assembly Master Mix (NEB) under ampicillin selection
following the manufacturer’s protocol. Ab variable regions were sequenced by Sanger sequencing.
Ab heavy and light plasmids generated through B cell sorting were co-transfected at a 1:1 ratio into HEK293F cells (Thermofisher)
using PEI Max 40K (linear polyethylenimine hydrochloride, Polysciences, Inc.). Ab supernatants were harvested four days following
transfection and purified using protein G affinity chromatography following the maunfacturers protocol (GE Healthcare).
Fab cloning and expression
Fab fragments were cloned from hybridoma cells, using the RNA extraction (RNAeasy, QIAGEN) and RT-PCR strategy described
above. Isolated DNA for Fab fragments was then cloned into the pHLsec vector. A C-terminal His6-tag was included in the heavy
chain construct and both chains were co-expressed (1:1 (w/w) ratio of Fab heavy to light chain expressing plasmids) in HEK293T
cells and purified by immobilized nickel-affinity chromatography (5mL HisTrap FF crude column and A¨KTA FPLC system, GEHealth-
care) followed by SEC into a buffer containing 10 mM TRIS pH 8.0, 150 mM NaCl.
Ab binding experiments
High binding ELISA 96 half-well microplates (Corning) were coated with purified RVFV Gn (25 mL, 3 mg/mL in PBS) overnight at 4C.
Plates were washed five times with PBS containing 0.05% Tween20 (PBS-T) and blocked with blocking buffer (5% non-fat milk in
PBS-T) for 1 h at RT. The blocking buffer was removed and serial diluted Ab (starting at 50 mg/mL, 1:5 dilution in blocking buffer)
was added for 2 h at RT. Plates were washed five times with PBS-T. Secondary Ab (goat anti-rabbit IgG F(ab’)2, AP conjugate, In-
vitrogen, 1:1000) was added for 1 h and plates were washed, as described above. The p-nitrophenyl phosphate substrate (Sigma)
was added to detect binding and the ODs were measured at 405 nm.
An ELISA to determine cross-reactivity between RV-Gn1 and SFTSV Gn was also performed. The ELISA was performed as above:
plates were coated with either RVFV Gn or SFTSVGn, serially diluted RV-Gn1 (starting at 10mg/ml, 1:5 dilution in blocking buffer) was
used for primary detection, and goat anti-rabbit was used for secondary detection. The Pierce TMB substrate kit (ThermoFisher) was
added to detect binding and OD were measured at 450 nm.
Fab fragment competition ELISA
ELISA plates were coated and blocked as above. Serial diluted Fab fragments were added (starting at 100 mg/ml, 1:5 dilution in block-
ing buffer) for 30min, and then equal volumes of the competing Abs were added at a constant concentration (twice the IC80 RVFVGn
binding concentration) for 1.5 h at RT. Biotinylated Fc specific rabbit cross-reactive secondary Ab (goat anti-mouse IgG Fc, biotin
conjugate, Invitrogen, 1:200) was added for 30 min. The plates were washed as above and alkaline phosphatase conjugated Strep-
tavidin (Insight Biotechnologies, 1:1000) was added for 30 min. Plates were washed and competition detected as described above.
Plaque reduction neutralization test
100 mL of three-fold serial-dilutedMab or control Ab (anti-HIVmonoclonal Ab PG9 (Walker et al., 2011;Walker et al., 2009)) wasmixed
with an equal volume of 100 plaque forming units (pfu.) RVFV ZH501 at 37C for 1h. The virus–Abmix was then transferred to 80–90%
confluent Vero cells in a 24-well plate and incubated at 37C for 1 h. After incubation liquid overlay, MEM with (1% avicel, 10% FBS,Cell Reports 25, 3750–3758.e1–e4, December 26, 2018 e3
1% antibiotic/antimycotic solution) was added. The plates were then incubated for 3–4 days, and fixed and stained, as described
above. Plaques were then counted for each well and the neutralization percentage was calculated relative to the corresponding
PG9 Mab control. IC50 values were calculated in GraphPad Prism using a least-squares non-linear fit dose-response curve.
Crystallization and structure determination
RVFV Gn and RV-Gn1 were complexed and purified by SEC using a Superdex 200 10/300 Increase column (GE Healthcare). The
RVFV Gn–RV-Gn1 complex was crystallized using the sitting drop vapor diffusion method (Walter et al., 2005) after 185 days
at RT at a concentration of 9.5 mg mL1, by mixing 100 nL of protein in 10 mM TRIS pH 8.0, 150 mM NaCl buffer and 100 nL
20% w/v PEG 500, 0.1 M bis-Tris pH 6.5. Crystals were cryo-cooled in the precipitant containing 25% glycerol.
X-ray data were recorded at Beamline I03 at Diamond Light Source (Didcot, UK) on a Pilatus 6MF detector (Dectris). X-ray data
were indexed, integrated, and scaled with XIA2 (Winter, 2010). The structure of RVFV Gn–RV-Gn1 was phased bymolecular replace-
ment with PHASER (McCoy et al., 2007) using the crystal structures of a rabbit Fab fragment (PDB:4J02) as a search model. Iterative
model building was performed with COOT (Emsley and Cowtan, 2004). Structure refinement was performed with Refmac5 (Murshu-
dov et al., 2011) in the CCP4 suite. The final refined structure was validated with MolProbity (Chen et al., 2010).
QUANTIFICATION AND STATISTICAL ANALYSIS
Phylogenetic and molecular evolution analysis
Publicly available sequences encoding the full-length RVFV M segment (3600 bp) with known sample dates were obtained from
GenBank and manually aligned. The final sequence alignment comprised 98 sequences, sampled from 1951 to 2010. An initial
neighbor-joining tree was constructed in Geneious v 8.1.3 (http://www.geneious.com, (Kearse et al., 2012) using a HKY nucleotide
substitution model and 100 bootstrap replicates. The presence of a sufficient temporal signal in the alignment for molecular clock
analysis was confirmed using TempEst (Rambaut et al., 2016). For the dN/dS analysis, Bayesian molecular clock phylogenies
were estimated using BEAST v1.8.4 (Drummond et al., 2012). We used a log-normal relaxed molecular clock model (Drummond
et al., 2006), a Bayesian Skygrid coalescent prior (Gill et al., 2013), and a codon-structured nucleotide substitution model (Shapiro
et al., 2006). Two independent MCMC runs of 50 million steps were computed to ensure that stationarity and convergence had
been achieved. An empirical distribution of 9,000 molecular clock phylogenies was obtained by combining (after the removal of bur-
nin) the posterior tree distributions of each run. This empirical distribution was used subsequently to estimate dN/dS ratios using the
renaissance countingmethod (Lemey et al., 2012) implemented in BEAST v1.8.4. The alignment was partitioned into RVFVGn andGc
glycoproteins, and the RVFV Gn was subdivided further into domains A, B, and the b-ribbon domain (b). Hierarchical priors were
applied to the substitution model parameters for each partition, which enabled statistical strength for individual parameters to be
shared across different partitions (Suchard et al., 2003). Two independent MCMC runs of 10 million steps were computed for this
analysis using BEAST version 1.8.4.
DATA AND SOFTWARE AVAILABILITY
Atomic coordinates and structure factors of the RVFV Gn-RV-Gn1 complex have been deposited in the PDB (accession code 6I9I).e4 Cell Reports 25, 3750–3758.e1–e4, December 26, 2018
